COLORECTAL SCREENING PROGRAMME: IMPACT ON THE HOSPITAL S PATHOLOGY SERVICES SINCE ITS INTRODUCTION.
|
|
- Trevor Williamson
- 6 years ago
- Views:
Transcription
1 The West London Medical Journal 2009 Vol No 1 pp COLORECTAL SCREENING PROGRAMME: IMPACT ON THE HOSPITAL S PATHOLOGY SERVICES SINCE ITS INTRODUCTION. Competing interests: None declared ABSTRACT Sarah E Reynolds, Caroline Finlayson Aims: This study examined the impact of introducing the colorectal cancer screening programme on our hospital s pathology service. Methods: We compared the workload figures and main histological diagnoses found in biopsies from 82 patients referred for colonoscopy through the colorectal cancer (CRC) screening programme in January-June 2007 with those from 80 patients referred with lower GI symptoms (e.g. change in bowel habit) in the corresponding period in The absolute numbers of biopsies taken were compared to reflect the increase in patient numbers as a result of the introduction of the screening programme. Results: There was a 69.5% increase in specimen numbers in 2007 as a result of screening. FOB positive (Faecal Occult Blood) patients generated a significantly higher mean Welcan units per referral (p<0.05). FOB positive patients had a significantly larger mean maximum sample size (p<0.05). The main diagnoses made on the biopsies sent from the pre-screening group were normal mucosa (39.04%) and tubular adenoma (32.93%) with relatively few adenocarcinomas in this group (4.89%). On the other hand, in the FOB positive group, only 6.25% of the biopsies were histologically normal; the primary histological diagnosis for nearly half the patients was tubular adenoma (48.75%) and 10% of biopsies showed adenocarcinoma. Conclusion: Screening has significantly increased the workload of the histopathology department. A higher proportion of biopsies showing adenomatous polyps and adenocarcinoma were detected in the screening group, compared with patients who presented with lower GI tract symptoms. 23
2 INTRODUCTION 50% of CRC (colorectal cancer) cases occur in people aged years 1. Screening for colorectal cancer (CRC) using the faecal occult blood (FOB) test involves sending home testing kits biannually to adults in this age range, but patients aged >70 can participate by request. Pilot studies have shown that approximately 2% of individuals test positive and are sent for further investigation by colonoscopy (or barium enema if colonoscopy is not possible). Our hospital entered the screening programme in November Only one biopsy was received in December 2006, so our study examines the first 6 months of Price et al 2 demonstrated that the screening programme had a significant impact on hospital diagnostic services. The paper (based on audit data and questionnaire responses) showed an increased usage of the colonoscopy services of 21-31% as a result of investigating the FOB positive patients. The impact of the CRC screening trial at the primary care level was examined in a retrospective survey and audit by Jepson et al 3. The authors demonstrated an increase in primary care workload (mainly advice and information provision) as a consequence of the introduction of CRC screening program. We were interested to see what impact CRC screening would have on the histopathology department. Method The pathology reports were obtained for all 80 screening-detected FOBt (test) positive patients biopsied at colonoscopy during the period Jan 07 Jun 07 (the initial stages of our hospital s participation in the NBS programme). The eligibility for participation in the NBS programme is people aged years, but people aged over 70 years can also request test kits from their GPs. Sixteen patients were over 70 years. We compared the CRC screening group with the 82 symptomatic patients aged years referred to colonoscopy for investigation of symptoms such as change in bowel habit or anaemia during the period Jan 06 - Jun 06 (choosing the previous year ensured that there could be no confusion between the patient populations). This age group was selected in order to make the target groups comparable. Only patients referred for symptomatic investigation were included; those seen for routine surveillance (e.g. known inflammatory bowel disease or with a previous history of adenomatous polyps or lower gastrointestinal tract cancer) were excluded. 24
3 The workload impact of the CRC screening programme on pathology services was examined in terms of Welcan units for the biopsies taken in the two patient groups over each six month period. Welcan units measure the laboratory impact of specimen processing, cutting and staining, the number of levels taken through the block and any extra stains. For the purposes of this study the pathology from the symptomatic patients presenting in 2006 was compared with that from the screening patients in The following parameters were considered as measures of trial impact: 1) Absolute number of colorectal biopsy reports issued during the periods Jan-Jun 06 and Jan-Jun 07; 2) Welcan units unit of pathology workload; 3) Number of sample pots; 4) Histological sample size. Methodological points: Patients who presented more than once in the same period were counted as separate events. A specimen included all biopsies taken from a patient during one endoscopy thus the number of sample pots per patient varied between specimens. Only colorectal samples were included in the study (separate terminal ileal biopsies were excluded). Results. Specimen numbers: There was a 69.5% increase in specimen numbers in the first six months of 2007 compared the same time period in 2006 (figures 1.1 and 1.2). The total number of symptomatic patients aged years seen in 2007 (n=59) slightly decreased compared to those seen in the first six months of 2006 (n=82). Workload: workload was measured in Welcan units (table 2). As data was not normally distributed a Mann-Witney U test was performed to establish whether the two groups were drawn from similar populations. Null hypothesis: pre-screening and screening patients were drawn from the same population regarding Welcan units per referral. 25
4 Alternative hypothesis: pre-screening and postscreening patients were drawn from different populations regarding Welcan units per referral. P equalled 0.001, therefore as p<0.05 the null hypothesis was rejected and it was concluded that there is a statistically significant difference at the 5% level between the two populations. Number of sample pots: the number of sample pots sent to pathology per referral in the two groups is shown in table 3. There was no significant difference between the groups. Maximum sample size: The maximum sample size in each referral is shown in table 4. A Mann-Witney U test was performed to see if the two groups were drawn from different samples regarding to maximum sample size. Null hypothesis: pre-screening and screening patients were drawn from the same population regarding maximum sample size per referral. Alternative hypothesis: pre-screening and screening patients were drawn from different populations regarding maximum sample size per referral. P equalled therefore as p<0.05 the null hypothesis is rejected, i.e. there is a significant difference between the two groups with regards to maximum sample size at the 5% level. Histological diagnosis: A summary of the main histological diagnoses made in the biopsies from the two patient groups is shown in Table 5. Ranking of histological diagnosis is as follows: 1) Adenocarcinoma 2) Tubular adenoma 3) Tubulovillous adenoma 4) Serrated adenoma 5) Hyperplastic polyp 6) Inflammatory bowel disease 7) Angiodysplasia 8) Non-adenocarcinoma malignancy 9) Miscellaneous diagnoses 10) Normal Geographical distribution: We also compared the locations within the colon at which neoplastic polyps and cancers were encountered in the two groups. Although there were slightly more right sided and slightly few left 26
5 sided lesions in the FOB positive group, the findings were not significantly different. DISCUSSION The efficacy of the FOBt screening method in reducing colorectal cancer mortality was confirmed in a review of the Denmark arm of the FOBt trail 4 showed a significant reduction in the risk of CRC mortality in the screening group compared to the general population over a thirteen year period. The Nottingham hub also showed that FOBt diagnosed a higher proportion of CRC tumours of a less advanced stage than those which presented symptomatically over a ten year period 5. The staggered introduction of the screening programme to UK hospitals followed a review of trials by the national screening committee (NSC) 6 confirmed the efficacy of the FOB screening test. In this study we found a 69.5% increase in specimen numbers in patients aged years (the target age for bowel cancer screening) in 2007, reflecting an increase in patients as a result of screening (16 patients in the screened group were >70 years old and had opted in to the programme). Several characteristics were used to compare the screening-detected FOB positive patients with an equivalent symptomatic patient group from the prescreening era. In terms of the laboratory workload, FOB positive patients were found to have significantly higher mean Welcan units per referral. There was no significant difference between the two populations with respect to number of pots sent to pathology. However, FOB positive patients had a significantly larger mean maximum sample size. Although the analytical aspects were not formally addressed, an informal discussion with the pathologists involved in reporting the screening specimens indicated that the interpretation of torted, inflamed and ulcerated polyps from the group with positive FOB tests was more problematic. In particular, the differentiation of true invasive malignancy from pseudoinvasion due to torsion, added considerably to the time required for slide interpretation. Multiple levels were routinely employed in the FOB positive group in order to speed up the turnaround time to comply with the screening target, whereas levels were used more judiciously in the symptomatic group. The most surprising difference between the two study groups was that of the main (most significant) histological diagnosis. The main diagnoses made on the biopsies sent from the pre-screening group were normal mucosa (39.04%) and tubular adenoma (32.93%) with relatively few adenocarcinomas in this group (4.89%). In the FOB positive group, only 6.25% of the biopsies 27
6 were histologically normal; the primary histological diagnosis for nearly half the patients was tubular adenoma (48.75%) and 10% of biopsies showed adenocarcinoma. CONCLUSION Following the introduction of the screening program there was a 70% increase in colorectal biopsy specimen numbers over the six months (Jan-Jun) period in 2007 compared with the previous year. The workload (Welcan units) generated by the FOB positive (screening) patients was significantly higher, reflecting the increased mean maximum sample size per referral (larger polyps and biopsies take longer to examine histologically). Interestingly, samples from the FOB positive patients tended to be larger and more complex than those from the symptomatic patients, requiring more in-depth histological interrogation. A pleasing finding was the significant reduction in the number of normal biopsies received in the FOB positive group, compared with the high percentage obtained from the symptomatic group. A higher proportion of adenomatous polyps and adenocarcinomas were detected in the FOB positive patients confirming that the screening programme was effective in detecting cancerous and precancerous lesions. Due to the increased complexity of the screening programme samples, the programme s introduction represents a significant increase in pathology workload in this centre. Acknowledgements and thanks must go to Dr Finlayson (Pathology) and Mr Leicester (Endoscopy) and the Endoscopy Unit staff at St George s Hospital for their assistance and for allowing me access to their data. 28
7 APPENDIX Table 1. Colorectal biopsy patients in the first 6 months of 2006 and 2007 * Of the FOB positive (n=80) patients sixteen were seventy or over at the time of pathology referral Pre-screening (Jan-Jun 2006) Postscreening (Jan-Jun 2007) Total number of pathology reports % 139* 42.45% Percentage of pathology reports from symptomatic patients Table 2: Welcan units per referral Pre-screening (n=82) FOB positive (n=80) Mean (mm) Standard Deviation Range Table 3: Number of pots per referral Pre-screening Symptomatic patients (n=82) Screening FOBpositive Patients (n=80) Mean Standard Deviation Range Sum
8 Table 4: Maximum sample size per referral Prescreeing (n=82) FOBpositive (n=80) Mean (mm) Standard Deviation Range Table 5: Summary of main histological diagnoses Prescreening 2006 Screening 2007 (n=80) (n=82) Adenocarcinoma 4 8 Tubular Adenoma Tubullovilous 5 7 Adenoma Hyper/Metaplastic 11 8 Polyp Inflammatory Bowel 1 5 Disease Angiodysplasia 1 Other cancers 1 Miscellaneous 1 6 Normal 23 5 References 1. Lieberman D, Sleisenger MH. Is it time to recommend screening for colorectal cancer? Lancet 1996;348: Price J, Campbell C, Sells J, Kenicer M, Dunlop M, Weller D, Campbell H. Impact of UK Colorectal Cancer Screening Pilot on hospital diagnostic services Journal Public Health 27:3 p Jepson R, Weller D, Alexander F, Walker J. Impact of UK Colorectal Cancer Screening Pilot on primary care British Journal General Practice 2005 Mar; 55(512): D Jørgensen, O Kronborg and C Fenger. A randomised study of screening for colorectal cancer using faecal occult blood testing: results after 13 years and seven biennial screening rounds. Gut 2002 Jan; 50(1):
9 5. Hardcastle JD, Thomas WM, Chamberlain J, et al. Randomised controlled trial of faecal occult blood screening for colorectal cancer: the results of the first subjects. Lancet 1989; I : National Screening Committee. A summary of the colorectal cancer screening workshops and background papers, Available at 31
Pathology in Slovenian CRC screening programme:
Pathology in Slovenian CRC screening programme: Findings, organisation and quality assurance Snježana Frković Grazio University Medical Center Ljubljana, Slovenia Slovenia s population: 2 million Incidence
More informationPathology in Slovenian CRC screening programme: Organisation and quality assurance. Snježana Frković Grazio and Matej Bračko
Pathology in Slovenian CRC screening programme: Organisation and quality assurance Snježana Frković Grazio and Matej Bračko June 2009 to December 2013 (first three rounds) 33 969 colonoscopies were performed
More information05/07/2018. Organisation. The English screening programme what is happening? Organisation. Bowel cancer screening in the UK is:
Organisation The English screening programme what is happening? Phil Quirke Lead Pathologist Bowel Cancer Screening PHE England Bowel Cancer Screening Pathology Committee Started 2006 with roll out 4 devolved
More informationQuality ID #343: Screening Colonoscopy Adenoma Detection Rate National Quality Strategy Domain: Effective Clinical Care
Quality ID #343: Screening Colonoscopy Adenoma Detection Rate National Quality Strategy Domain: Effective Clinical Care 2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY MEASURE TYPE: Outcome DESCRIPTION:
More informationADENOMA SURVEILLANCE BCSP Guidance Note No 1 Version 1 September 2009
ADENOMA SURVEILLANCE BCSP Guidance Note No 1 Version 1 September 2009 Published by: NHS Cancer Screening Programmes Fulwood House Old Fulwood Road Sheffield S10 3TH Tel: 0114 271 1060 Fax: 0114 271 1089
More informationNorthern Ireland Bowel Cancer Screening Programme. Pathways. Version 4 1 st October 2013
Northern Ireland Bowel Cancer Screening Programme Pathways These changes will be version controlled, led by the Quality Assurance Director for the Programme. Any updated versions will be circulated and
More informationColorectal cancer screening
26 Colorectal cancer screening BETHAN GRAF AND JOHN MARTIN Colorectal cancer is theoretically a preventable disease and is ideally suited to a population screening programme, as there is a long premalignant
More informationC olorectal cancer (CRC) is the second most common
CANCER Effect of faecal occult blood screening on mortality from colorectal cancer: results from a randomised controlled trial J H Scholefield, S Moss, F Sufi, C M Mangham, J D Hardcastle... See end of
More informationSCREENING FOR BOWEL CANCER USING FLEXIBLE SIGMOIDOSCOPY REVIEW APPRAISAL CRITERIA FOR THE UK NATIONAL SCREENING COMMITTEE
SCREENING FOR BOWEL CANCER USING FLEXIBLE SIGMOIDOSCOPY REVIEW APPRAISAL CRITERIA FOR THE UK NATIONAL SCREENING COMMITTEE The Condition 1. The condition should be an important health problem Colorectal
More informationThe effectiveness of telephone reminders and SMS messages on compliance with colorectal cancer screening: an open-label, randomized controlled trial
Page1 of 5 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 The effectiveness of telephone reminders and SMS messages on compliance with colorectal cancer screening: an
More informationNATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE SCOPE
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE 1 Guideline title SCOPE Colorectal cancer: colonoscopic surveillance for prevention of colorectal cancer in patients with ulcerative colitis, Crohn
More informationAlberta Colorectal Cancer Screening Program (ACRCSP) Post Polypectomy Surveillance Guidelines
Alberta Colorectal Cancer Screening Program (ACRCSP) Post Polypectomy Surveillance Guidelines June 2013 ACRCSP Post Polypectomy Surveillance Guidelines - 2 TABLE OF CONTENTS Background... 3 Terms, Definitions
More informationBowel Cancer Screening
Bowel Cancer Screening Dr John Hancock FRCP Consultant Gastroenterologist University Hospital of North Tees Outline Background Current bowel cancer screening programme Tees Screening Centre Future Flexi
More informationScreening & Surveillance Guidelines
Chapter 2 Screening & Surveillance Guidelines I. Eligibility Coloradans ages 50 and older (average risk) or under 50 at elevated risk for colon cancer (personal or family history) that meet the following
More information2019 COLLECTION TYPE: MIPS CLINICAL QUALITY MEASURES (CQMS) MEASURE TYPE: Outcome High Priority
Quality ID #343: Screening Colonoscopy Adenoma Detection Rate National Quality Strategy Domain: Effective Clinical Care Meaningful Measure Area: Preventive Care 2019 COLLECTION TYPE: MIPS CLINICAL QUALITY
More informationPrevention of Bowel Cancer: which patients do I send for colonoscopy?
Prevention of Bowel Cancer: which patients do I send for colonoscopy? Dr Chris Groves Consultant Gastroenterologist and Honorary Senior Lecturer St George s Hospital and Medical School Director, SW London
More informationFaecal Immunochemical Testing (FIT) for Screening and Symptomatic Patients
Faecal Immunochemical Testing (FIT) for Screening and Symptomatic Patients Caroline Addison NE BCSP Hub Director and Consultant Clinical Scientist What is FIT Type of Faecal Occult Blood test Designed
More informationNHS KINGSTON. Contents
NHS KINGSTON Contents 1. Background... 2 2. Targets and quality standards... 2 3. Service provision and performance... 3 Uptake... 3 Investigations... 6 Cancer detection... 7 Age extension... 7 4. Quality
More informationCLINICAL PRACTICE GUIDELINE FOR COLORECTAL CANCER SCREENING
CLINICAL PRACTICE GUIDELINE FOR COLORECTAL CANCER SCREENING This guideline is designed to assist practitioners by providing the framework for colorectal cancer (CRC) screening, and is not intended to replace
More informationFrequency of Diagnosis of Colorectal Cancer with Double Contrast Barium Enema
Bahrain Medical Bulletin, Vol.24, No.3, September 2002 Frequency of Diagnosis of Colorectal Cancer with Double Contrast Barium Enema Najeeb S Jamsheer, MD, FRCR* Neelam. Malik, MD, MNAMS** Objective: To
More informationMeasure #343: Screening Colonoscopy Adenoma Detection Rate National Quality Strategy Domain: Effective Clincal Care
Measure #343: Screening Colonoscopy Adenoma Detection Rate National Quality Strategy Domain: Effective Clincal Care 2016 PQRS OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY DESCRIPTION: The percentage
More informationGUIDANCE ON THE INDICATIONS FOR DIAGNOSTIC UPPER GI ENDOSCOPY, FLEXIBLE SIGMOIDOSCOPY AND COLONOSCOPY
Position Statement produced by BSG, AUGIS and ACPGBI GUIDANCE ON THE INDICATIONS FOR DIAGNOSTIC UPPER GI ENDOSCOPY, FLEXIBLE SIGMOIDOSCOPY AND COLONOSCOPY Introduction In 2011 the Independent Practice
More informationTHE NEW ZEALAND MEDICAL JOURNAL
THE NEW ZEALAND MEDICAL JOURNAL Vol 120 No 1258 ISSN 1175 8716 A survey of colonoscopy capacity in New Zealand s public hospitals Andrew Yeoman, Susan Parry Abstract Aims Population screening for colorectal
More informationNorth West London Pathology. Faecal Occult Blood testing. Mrs Sophie Barnes FRCPath Consultant Clinical Scientist
Faecal Occult Blood testing Mrs Sophie Barnes FRCPath Consultant Clinical Scientist Learning objectives Background Guidelines for colorectal cancer detection Tests available to detect occult blood in faeces
More informationObjectives. Definitions. Colorectal Cancer Screening 5/8/2018. Payam Afshar, MS, MD Kaiser Permanente, San Diego. Colorectal cancer background
Colorectal Cancer Screening Payam Afshar, MS, MD Kaiser Permanente, San Diego Objectives Colorectal cancer background Colorectal cancer screening populations Colorectal cancer screening modalities Colonoscopy
More informationFECAL OCCULT BLOOD TEST
MEDICAL POLICY For use with the UnitedHealthcare Laboratory Benefit Management Program, administered by BeaconLBS FECAL OCCULT BLOOD TEST Policy Number: CMP - 023 Effective Date: January 1, 2018 Table
More informationLIST OF ABBREVIATIONS
Gastroenter oenterology 2005 Royal College of Physicians of Edinburgh Screening and surveillance for upper and lower gastrointestinal cancer JN Plevris Consultant Gastroenterologist and Honorary Senior
More informationBowel Cancer Prevention and Screening. Harriet Wynne, Cancer Council Victoria
Bowel Cancer Prevention and Screening Harriet Wynne, Cancer Council Victoria New cases and deaths for the Victoria population in 2013 Thursfield V, et al. Cancer in Victoria: Statistics & trends 2013.
More informationColorectal Neoplasia. Dr. Smita Devani MBChB, MRCP. Consultant Physician and Gastroenterologist Aga Khan University Hospital, Nairobi
Colorectal Neoplasia Dr. Smita Devani MBChB, MRCP Consultant Physician and Gastroenterologist Aga Khan University Hospital, Nairobi Case History BT, 69yr male Caucasian History of rectal bleeding No change
More informationPatologia sistematica V Gastroenterologia Prof. Stefano Fiorucci. Colon polyps. Colorectal cancer
Patologia sistematica V Gastroenterologia Prof. Stefano Fiorucci Colon polyps Colorectal cancer Harrison s Principles of Internal Medicine 18 Ed. 2012 Colorectal cancer 70% Colorectal cancer CRC and colon
More informationFIT for symptomatic patients. Facilitator name
FIT for symptomatic patients Facilitator name Context colorectal cancer Colorectal cancer in the UK 41,804 new cases in 2015 15,903 deaths in 2014 Fourth most common cancer Second most common cause of
More informationCite this article as: BMJ, doi: /bmj c (published 5 July 2004)
Cite this article as: BMJ, doi:10.1136/bmj.38153.491887.7c (published 5 July 2004) Results of the first round of a demonstration pilot of screening for colorectal cancer in the United Kingdom UK Colorectal
More informationRandomised study of screening for colorectal cancer with faecaloccult-blood
Articles Randomised study of screening for colorectal cancer with faecaloccult-blood test Ole Kronborg, Claus Fenger, Jørn Olsen, Ole Dan Jørgensen, Ole Søndergaard Summary Background Case-control studies
More informationQuality ID #439: Age Appropriate Screening Colonoscopy National Quality Strategy Domain: Efficiency and Cost Reduction
Quality ID #439: Age Appropriate Screening Colonoscopy National Quality Strategy Domain: Efficiency and Cost Reduction 2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY MEASURE TYPE: Efficiency DESCRIPTION:
More informationHealth Professional Information
Bowel Screening Wales Health Professional Information 2011 www.bowelscreeningwales.org.uk Version 2.0 Acknowledgements Bowel Screening Wales would like to express their sincere thanks to the English and
More informationPolypectomy and Local Resections of the Colorectum Structured Pathology Reporting Proforma
Polypectomy and Local Resections of the Colorectum Structured Pathology Reporting Proforma Mandatory questions (i.e. protocol standards) are in bold (e.g. S1.03). Family name Given name(s) Date of birth
More informationColon Cancer Screening. Layth Al-Jashaami, MD GI Fellow, PGY 4
Colon Cancer Screening Layth Al-Jashaami, MD GI Fellow, PGY 4 -Colorectal cancer (CRC) is a common and lethal cancer. -It has the highest incidence among GI cancers in the US, estimated to be newly diagnosed
More informationremoval of adenomatous polyps detects important effectively as follow-up colonoscopy after both constitute a low-risk Patients with 1 or 2
Supplementary Table 1. Study Characteristics Author, yr Design Winawer et al., 6 1993 National Polyp Study Jorgensen et al., 9 1995 Funen Adenoma Follow-up Study USA Multi-center, RCT for timing of surveillance
More informationGuidelines for Breast, Cervical and Colorectal Cancer Screening
Guidelines for Breast, Cervical and Colorectal Cancer Screening Your recommendation counts. Talk to your patients about screening for cancer. CancerCare Manitoba provides organized, population-based screening
More informationExperience and challenges of implementing optical diagnosis into clinical practice UK and European Perspective
Experience and challenges of implementing optical diagnosis into clinical practice UK and European Perspective WEO Image Enhanced Endoscopy San Diego, USA Dr James East Consultant Gastroenterologist Honorary
More informationDysplasia 4/19/2017. How do I practice Chromoendoscopy for Surveillance of Colitis? SCENIC: Polypoid Dysplasia in UC. Background
SCENIC: Polypoid in UC Definition How do I practice for Surveillance of Colitis? Themos Dassopoulos, M.D. Director, BSW Center for IBD Themistocles.Dassopoulos@BSWHealth.org Tel: 469-800-7189 Cell: 314-686-2623
More informationReferral Criteria for Direct Access Outpatient Colonoscopy or Computed Tomography Colonography
Referral Criteria for Direct Access Outpatient Colonoscopy or Computed Tomography Colonography 2019 Released 2019 health.govt.nz Citation: Ministry of Health. 2019. Referral Criteria for Direct Access
More informationSurveying the Colon; Polyps and Advances in Polypectomy
Surveying the Colon; Polyps and Advances in Polypectomy Educational Objectives Identify classifications of polyps Describe several types of polyps Verbalize rationale for polypectomy Identify risk factors
More informationInformation Pack for GP s The implementation of the Faecal Immunochemical Test (FIT) across the South West
Information Pack for GP s The implementation of the Faecal Immunochemical Test (FIT) across the South West The South West Cancer Alliances have been awarded transformation funding to provide access to
More informationEmerging Interventions in Endoscopy. Margaret Vance Nurse Consultant in Gastroenterology St Mark s Hospital
Emerging Interventions in Endoscopy Margaret Vance Nurse Consultant in Gastroenterology St Mark s Hospital Colon Cancer Colon cancer is common. 1 in 20 people in the UK will develop the disease 19 000
More informationThis is the portion of the intestine which lies between the small intestine and the outlet (Anus).
THE COLON This is the portion of the intestine which lies between the small intestine and the outlet (Anus). 3 4 5 This part is responsible for formation of stool. The large intestine (colon- coloured
More informationDr Alasdair Patrick. Dr Nagham Al-Mozany. 9:45-10:10 Where Are We Up To With Bowel Cancer Screening?
Dr Alasdair Patrick Gastroenterologist and General Physician Middlemore Hospital Auckland Dr Nagham Al-Mozany Colorectal Surgeon Auckland City Hospital Clinical Senior Lecturer University of Auckland 9:45-10:10
More informationStructured Follow-Up after Colorectal Cancer Resection: Overrated. R. Taylor Ripley University of Colorado Grand Rounds April 23, 2007
Structured Follow-Up after Colorectal Cancer Resection: Overrated R. Taylor Ripley University of Colorado Grand Rounds April 23, 2007 Guidelines for Colonoscopy Production: Surveillance US Multi-Society
More informationTransforming Cancer Services for London
Programme Director Paul Roche Status Draft Owner Laura Boyd Version 0.4 Author Jennifer Layburn Date 15/05/13 Transforming Cancer Services for London Best Practice Commissioning Pathway for the early detection
More informationNeoplastic Colon Polyps. Joyce Au SUNY Downstate Grand Rounds, October 18, 2012
Neoplastic Colon Polyps Joyce Au SUNY Downstate Grand Rounds, October 18, 2012 CASE 55M with Hepatitis C, COPD (FEV1=45%), s/p vasectomy, knee surgery Meds: albuterol, flunisolide, mometasone, tiotropium
More informationUK Bowel Cancer screening Dr Voi Shim Wong BsC MD FRCP. Consultant Gastroenterologist Accredited BCSP colonoscopist Whittington + UCL Hospitals
UK Bowel Cancer screening 2017 Dr Voi Shim Wong BsC MD FRCP Consultant Gastroenterologist Accredited BCSP colonoscopist Whittington + UCL Hospitals Bowel Cancer Contents UK Bowel Cancer Screening Programme
More informationDIGESTIVE SYSTEM SURGICAL PROCEDURES May 1, 2015 INTESTINES (EXCEPT RECTUM) Asst Surg Anae
ENDOSCOPY Z50 Duodenoscopy (not to be claimed if Z399 and/or Z00 performed on same patient within 3 months)... 92.10 Z9 Subsequent procedure (within three months following previous endoscopic procedure)...
More informationThe Canadian Cancer Society estimates that in
How Do I Screen For Colorectal Cancer? By Ted M. Ross, MD, FRCS(C); and Naomi Ross, RD, BSc To be presented at the University of Toronto s Primary Care Today sessions (October 3, 2003) The Canadian Cancer
More informationC olorectal adenomas are reputed to be precancerous
568 COLORECTAL CANCER Incidence and recurrence rates of colorectal adenomas estimated by annually repeated colonoscopies on asymptomatic Japanese Y Yamaji, T Mitsushima, H Ikuma, H Watabe, M Okamoto, T
More informationFor identification, support and follow up related to Familial Gastrointestinal Cancer conditions. South Island Cancer Nurses Network September 2013
For identification, support and follow up related to Familial Gastrointestinal Cancer conditions South Island Cancer Nurses Network September 2013 Who are we? Specialist multidisciplinary team: Nurse coordinators,
More informationAn Update on the Bowel Cancer Screening Programme. Natasha Djedovic, London Hub Director 17 th September 2018
An Update on the Bowel Cancer Screening Programme Natasha Djedovic, London Hub Director 17 th September 2018 NHS Bowel Cancer Screening Programme 2006: 60-69 yr old men & women offered guaiac Faecal Occult
More informationCancer Screening Programmes BOWEL CANCER SCREENING. The Facts
Cancer Screening Programmes BOWEL CANCER SCREENING The Facts What is the aim of this leaflet? This leaflet gives you information about bowel cancer, and the benefits and risks of bowel cancer screening.
More informationScreening for GI Cancer Past Present and Future. Prof. Bob Steele University of Dundee
Screening for GI Cancer Past Present and Future Prof. Bob Steele University of Dundee Worldwide Cancer Incidence Rates UK Cancer Incidence Rates Screening The detection of disease in asymptomatic subjects
More information2012 update. Bowel Cancer. Information for people at increased risk of bowel cancer. Published by the New Zealand Guidelines Group
2012 update Bowel Cancer Information for people at increased risk of bowel cancer Published by the New Zealand Guidelines Group i Contents Introduction 1 The bowel 1 Bowel cancer 3 What are the symptoms
More informationCENTERS FOR DISEASE CONTROL AND PREVENTION CENTERS FOR DISEASE CONTROL AND PREVENTION. Incidence Male. Incidence Female.
A Call to Action: Prevention and Early Detection of Colorectal Cancer (CRC) 5 Key Messages Screening reduces mortality from CRC All persons aged 50 years and older should begin regular screening High-risk
More informationUpdates in Colorectal Cancer Screening & Prevention
Updates in Colorectal Cancer Screening & Prevention Swati G. Patel, MD MS Assistant Professor of Medicine Division of Gastroenterology & Hepatology Gastrointestinal Cancer Risk and Prevention Clinic University
More informationTHE NEW ZEALAND MEDICAL JOURNAL
THE NEW ZEALAND MEDICAL JOURNAL Journal of the New Zealand Medical Association Colonoscopy requirements of population screening for colorectal cancer in New Zealand Terri Green, Ann Richardson, Susan Parry
More informationManagement of pt1 polyps. Maria Pellise
Management of pt1 polyps Maria Pellise Early colorectal cancer Malignant polyp Screening programmes SM Invasive adenocar cinoma Advances in diagnostic & therapeutic endoscopy pt1 polyps 0.75 5.6% of large-bowel
More informationNHS Bowel Cancer Screening Programmes: Evaluation of pilot of Faecal Immunochemical Test : Final report.
NHS Bowel Cancer Screening Programmes: Evaluation of pilot of Faecal Immunochemical Test : Final report. Sue Moss, Christopher Mathews Centre for Cancer Prevention, Wolfson Institute, Queen Mary University
More informationGuidelines for Colonoscopy Surveillance After Screening and Polypectomy: A Consensus Update by the US Multi-Society Task Force on Colorectal Cancer
Guidelines for Colonoscopy Surveillance After Screening and Polypectomy: A Consensus Update by the US Multi-Society Task Force on Colorectal Cancer David A. Lieberman, 1 Douglas K. Rex, 2 Sidney J. Winawer,
More informationDiagnostics guidance Published: 10 May 2017 nice.org.uk/guidance/dg28
Virtual chromoendoscopy to assess colorectal polyps during colonoscopy Diagnostics guidance Published: 10 May 2017 nice.org.uk/guidance/dg28 NICE 2017. All rights reserved. Subject to Notice of rights
More informationThe Nottingham eprints service makes this work by researchers of the University of Nottingham available open access under the following conditions.
Morling, Joanne R. and Barke, A.N. and Chapman, C.J. and Logan, R.F. (2018) Could stool collection devices help increase uptake to bowel cancer screening programmes? Journal of Medical Screening. ISSN
More informationCOLORECTAL CANCER FAISALGHANISIDDIQUI MBBS; FCPS; PGDIP-BIOETHICS; MCPS-HPE
COLORECTAL CANCER FAISALGHANISIDDIQUI MBBS; FCPS; PGDIP-BIOETHICS; MCPS-HPE PROFESSOR OF SURGERY & DIRECTOR, PROFESSIONAL DEVELOPMENT CENTRE J I N N A H S I N D H M E D I C A L U N I V E R S I T Y faisal.siddiqui@jsmu.edu.pk
More informationBowel cancer screening and prevention
Bowel cancer screening and prevention Cancer Incidence and Mortality Victoria 2012 Number 6000 5000 4000 3000 2000 Incidences = 29,387 Mortality = 10,780 Incidence Mortality 1000 0 Prostate Breast Bowel
More informationEarly detection and screening for colorectal neoplasia
Early detection and screening for colorectal neoplasia Robert S. Bresalier Department of Gastroenterology, Hepatology and Nutrition. The University of Texas. MD Anderson Cancer Center. Houston, Texas U.S.A.
More informationColorectal Cancer Screening
Colorectal Cancer Screening An Integrated Care Pathway of the Collaborative Care Network Subject Matter Expert: Kevin Wolov, DO Pathway Custodian: Pat Czapp, MD First, a Friendly Reminder... This Integrated
More informationA microsimulation study of the benefits and costs of screening for colorectal cancer Christopher Eric Stevenson
A microsimulation study of the benefits and costs of screening for colorectal cancer Christopher Eric Stevenson A thesis submitted for the degree of Doctor of Philosophy of The Australian National University
More informationScreening for Colorectal Cancer: Se0ng it up and making it work. Julie8a Patnick 4 December 2014
Screening for Colorectal Cancer: Se0ng it up and making it work Julie8a Patnick 4 December 2014 Evaluation of the UK Colorectal Cancer Screening Pilot Two sites, population ~ 1m Coventry & Warwickshire
More informationCOLORECTAL CANCER: A CHALLENGE FOR HEALTHY LIFESTYLE, SCREENING AND PROPER CARE
COLORECTAL CANCER: A CHALLENGE FOR HEALTHY LIFESTYLE, SCREENING AND PROPER CARE Brno, 29 May 2015: For the fourth time in a row, the second largest city of the Czech Republic will host the European Colorectal
More informationEngaging Primary Care in bowel screening
Engaging Primary Care in bowel screening GP good practice guide for Wales December 2018 Together we will beat cancer Contents Background 3 The FIT screening pathway in Wales 4 The role of GP practices
More informationInformation for families with a slightly increased risk of bowel cancer. Family History of Bowel Cancer
Information for families with a slightly increased risk of bowel cancer Family History of Bowel Cancer How common is bowel cancer? Bowel cancer is the 3rd most common cancer in the UK. 1 in 20 people develop
More informationAn Introduction to MUTYH Associated Polyposis (MAP)
An Introduction to MUTYH Associated Polyposis (MAP) 1 An Introduction to MUTYH Associated Polyposis(MAP) Contents What is MUTYH Associated Polyposis (MAP)? 2 What causes MUTYH Associated Polyposis (MAP)?
More informationFecal occult blood tests: a cost-effectiveness analysis Gyrd-Hansen D
Fecal occult blood tests: a cost-effectiveness analysis Gyrd-Hansen D Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract
More informationGENETIC MANAGEMENT OF A FAMILY HISTORY OF FAP or MUTYH ASSOCIATED POLYPOSIS. Family Health Clinical Genetics. Clinical Genetics department
GENETIC MANAGEMENT OF A FAMILY HISTORY OF FAP or MUTYH ASSOCIATED POLYPOSIS Full Title of Guideline: Author (include email and role): Division & Speciality: GUIDELINES FOR THE GENETIC MANAGEMENT OF A FAMILY
More informationOutcomes of the Bowel Cancer Screening Programme (BCSP) in England after the first 1 million tests
Gut Online First, published on December 7, 2011 as 10.1136/gutjnl-2011-300843 Colorectal cancer 1 Division of Epidemiology and Public Health, University of Nottingham, Nottingham, UK 2 NHS Cancer Screening
More informationSupplementary Appendix
Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Kaminski MF, Regula J, Kraszewska E, et al. Quality indicators
More informationImplementation of Faecal Immunochemical Testing as the screening test for Bowel Screening. Programme in Wales
Immunochemical Testing as the screening test for Bowel Screening. Programme in Wales Information to Public Health Wales Board prior to introduction Author: Dr Sharon Hillier, Acting Director Screening
More informationPage 1. Is the Risk This High? Dysplasia in the IBD Patient. Dysplasia in the Non IBD Patient. Increased Risk of CRC in Ulcerative Colitis
Screening for Colorectal Neoplasia in Inflammatory Bowel Disease Francis A. Farraye MD, MSc Clinical Director, Section of Gastroenterology Co-Director, Center for Digestive Disorders Boston Medical Center
More informationColon Screening in 2014 Offering Patients a Choice. Clark A Harrison MD The Nevada Colon Cancer Partnership
Colon Screening in 2014 Offering Patients a Choice Clark A Harrison MD The Nevada Colon Cancer Partnership Objectives 1. Understand the incidence and mortality rates for CRC in the US. 2. Understand risk
More informationAnnual Report. Public Health Screening Programmes TO 31 MARCH Extract: Chapter 3 : Planning for Bowel Screening Programme
Public Health Screening Programmes Annual Report TO 31 MARCH 2007 Extract: Chapter 3 : Planning for Bowel Screening Programme Version 1.0 Published: 18 December 2007 1 Contents INTRODUCTION...3 SUMMARY...5
More informationColorectal Cancer Screening: Cost-Effectiveness and Adverse events October, 2005
Colorectal Cancer Screening: Cost-Effectiveness and Adverse events October, 2005 David Lieberman MD Chief, Division of Gastroenterology Oregon Health and Science University Portland VAMC Portland, Oregon
More informationWEO CRC SC Meeting. Barcelona, Spain October 23, 2015
WEO CRC SC Meeting Barcelona, Spain October 23, 2015 Identification of serrated polyposis syndrome in the context of population-based CRC screening programs Evelien Dekker Academic Medical Center Amsterdam,
More informationWhen is a programmed follow-up meaningful and how should it be done? Professor Alastair Watson University of Liverpool
When is a programmed follow-up meaningful and how should it be done? Professor Alastair Watson University of Liverpool Adenomas/Carcinoma Sequence Providing Time for Screening Normal 5-20 yrs 5-15 yrs
More informationColorectal Cancer Screening What are my options?
069-Colorectal cancer (Rosen) 1/23/04 12:59 PM Page 69 What are my options? Wayne Rosen, MD, FRCSC As presented at the 37th Annual Mackid Symposium: Cancer Care in the Community (May 22, 2003) There are
More informationThe Dutch bowel cancer screening program Relevant lessions for Ontario
The Dutch bowel cancer screening program Relevant lessions for Ontario Ernst J Kuipers Erasmus MC University Medical Center Rotterdam - The Netherlands 1 Ismar Boas (1858 1938) Colorectal cancer screening
More informationBowel screening cancer prevention
Bowel screening cancer prevention David S Morrison Consultant in Public Health Medicine 22 nd September 2016 Bowel cancer incidence since 1979 http://www.cancerresearchuk.org/healthprofessional/cancer-statistics/statistics-by-cancertype/bowel-cancer/incidence#heading-two
More informationTo: all bowel screening centre directors and programme managers. Dear colleague
Professor Julietta Patnick CBE Director JP/LC 11 January 2013 To: all bowel screening centre directors and programme managers Fulwood House Old Fulwood Road Sheffield S10 3TH Tel: 0114 271 1060 Fax: 0114
More informationBowel cancer risk in the under 50s. Greg Rubin Professor of General Practice and Primary Care
Bowel cancer risk in the under 50s Greg Rubin Professor of General Practice and Primary Care Prevalence of GI problems in the consulting population Thompson et al, Gut 2000 Number of patients % of patients
More informationBowel Cancer Screening Programme Eastern Hub Biennial Report July 2014
Bowel Cancer Screening Programme Eastern Hub Biennial Report 2012-2013 July 2014 Contents Bowel Cancer Screening Programme, Eastern Hub Biennial Report 2012-2013 Foreword 5 Executive Summary 6 1. Introduction
More informationBe it Resolved that FIT is the Best Way to Screen for Colorectal Cancer DEBATE
Be it Resolved that FIT is the Best Way to Screen for Colorectal Cancer DEBATE DEBATE Presenters PRESENTATION MODERATOR Dr. Praveen Bansal -MD, CCFP FCFP Regional Primary Care Lead, Integrated Cancer Screening,
More informationBowel Screening Wales E-Bulletin October 2010
Bowel Screening Wales E-Bulletin October 2010 News I am delighted to have returned to work after 5 months sick leave and would like to thank everyone for all their hard work and kind wishes while I was
More information2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY. MEASURE TYPE: Process
Quality ID #185 (NQF 0659): Colonoscopy Interval for Patients with a History of Adenomatous Polyps Avoidance of Inappropriate Use National Quality Strategy Domain: Communication and Care Coordination 2018
More informationColon Cancer Screening & Surveillance. Amit Patel, MD PGY-4 GI Fellow
Colon Cancer Screening & Surveillance Amit Patel, MD PGY-4 GI Fellow Epidemiology CRC incidence and mortality rates vary markedly around the world. Globally, CRC is the third most commonly diagnosed cancer
More informationSummary. Cezary ŁozińskiABDF, Witold KyclerABCDEF. Rep Pract Oncol Radiother, 2007; 12(4):
Rep Pract Oncol Radiother, 2007; 12(4): 201-206 Original Paper Received: 2006.12.19 Accepted: 2007.04.02 Published: 2007.08.31 Authors Contribution: A Study Design B Data Collection C Statistical Analysis
More information